A higher proportion of small, dense low-density lipoprotein (sdLDL) is known to be associated with a high prevalence of cardiovascular disease in association with metabolic syndrome (MS). Hypertension (HTN) is one of the known risk factors for MS. However, whether HTN is associated with sdLDL in patients without MS is not yet clear. The lipid profiles, including low-density-lipoprotein (LDL) subfractions, of 383 consecutive subjects were evaluated. The patients without MS consisted of 198 hypertensive patients (non-MS/HTN group) and 108 normotensive subjects (non-MS/non-HTN group). The peak and mean particle diameter of LDL were measured by gradient gel electrophoresis. Plasma total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride (TG), HDL cholesterol/Apo A1, LDL-C/ApoB and Apo(A1, B, CII and E) levels did not differ between the non-MS/non-HTN and non-MS/HTN groups. When analyzing LDL subfraction, the absolute amount of patterns A and B was not different between the non-MS/non-HTN and non-MS/HTN groups. Compared with the non-MS/non-HTN groups, the proportion of sdLDL was higher in the non-MS/HTN group (37.7% versus 39.9%, P ¼ 0.046), but not significant after adjustment of waist circumference, serum TG, age and statin usage. The proportion of sdLDL to total LDL was higher in hypertensive subjects, even those without MS, than in normotensive subjects. However, this difference of LDL subfraction in hypertensive patients is associated with higher waist circumference, higher serum TG, older age and more statin usage. This result suggests that HTN may contribute to atherosclerosis and endothelial dysfunction with associated risk factors that influence LDL size.
Introduction
Low-density lipoprotein (LDL) is a heterogeneous population of particles with respect to their size, density and chemical composition. 1 The predominance of small, dense LDL (sdLDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. 2 Austin et al. 1 first proposed a link between sdLDL and an increased risk of coronary artery disease (CAD). The observation that a preponderance of sdLDL increases the risk of CAD by up to sevenfold has been found in several case-control and prospective studies. [3] [4] [5] [6] [7] [8] [9] [10] The proposed mechanism is related to the biochemical behavior of sdLDL in that it exhibits reduced uptake by the LDL receptor, 11 is more susceptible to oxidation and phagocytosis, and demonstrates increased binding to proteoglycans of the vessel wall 12 when compared with large, buoyant LDL. It has been proposed that sdLDL may be related to endothelial dysfunction independent of LDL cholesterol, triglycerides (TG) and high-density lipoprotein (HDL) cholesterol. 13 Hypertension (HTN) is one of the well-known risk factors for atherosclerotic vascular diseases. Its exact mechanisms contributing to atherosclerosis have not been fully elucidated. Furthermore, little is known about the relationship between HTN and sdLDL.
Metabolic syndrome (MS) is known to be associated with an increased risk for cardiovascular disease (CVD). 14, 15 Individuals with MS have a three-to fivefold increased risk of diabetes and/or CVD, and a significantly increased cardiovascular mortality has been shown in epidemiological studies. 16, 17 In the Framingham Heart Study, both men and women with MS had a higher number of small LDL particles. 18 HTN is also a component of MS. In the Framingham Heart Study, patients with MS had systolic and diastolic blood pressures (DBPs) that were significantly correlated with small LDL particle number. 18 Although the roles of both insulin resistance and hypertriglyceridemia on the formation of sdLDL are well studied, few studies regarding the contribution of HTN to sdLDL formation have been published. Furthermore, the relationship between HTN and sdLDL is not well understood in patients without MS. Therefore, we evaluated the association between HTN and sdLDL in non-MS patients.
Methods
A total of 383 consecutive subjects were enrolled at the Korea University Guro Hospital from July 2008 to June 2009. The study population consisted of 306 patients without MS (198 HTN patients and 108 non-HTN patients) and 77 patients with three or more MS components (waist circumference 490 cm in men or 480 cm in women, TG X150 mg dl À1 , HDL cholesterol o40 mg dl À1 in men or o50 mg dl
À1
in women, systolic blood pressure X130 mmHg or DBP X85 mmHg and fasting blood glucose X100 mg dl À1 ). We excluded patients with hypertriglyceridemia (4200 mg dl À1 ) and diabetes to exclude metabolic effects on lipoprotein.
Individual medical history, laboratory data, BP and anthropometry (body mass index, waist circumference and hip circumference) were measured after informed, written consent was obtained from each patient. A patient with systolic blood pressure X140 mmHg and/or DBP X90 mmHg or taking anti-hypertensive medication was defined as having HTN. After an overnight fast, blood samples were taken. LDL particle size analysis was done with ultracentrifugation and gel electrophoresis over 5 days. We used the method described by Griffin et al. 19 in evaluating LDL particle size and the relative propotions of LDL I, LDL II and LDL III. On day 1, 6.4 ml of density solution (1.182 g ml À1 ) was added to a centrifuge tube, then 80 ml of plasma was added and overlaid with 33 ml of density solution (1.019 g ml À1 ). This was then centrifuged at 42 000 r.p.m. at 10 1C for 18 h. On day 2, the top 40 ml was removed and the remaining intranatent was added to a new tube with 29.4 ml of density solution (1.182 g ml À1 ) and was overlaid with 10.6 ml of density solution (1.063 g ml À1 ). This was then centrifuged at 42 000 r.p.m. at 10 1C for 18 h. On day 3, the top 40 ml was transferred to an Eppendorf tube and gradient gel electrophoresis over 24 h was performed. On day 4, the gel was fixed for 30 min in sulphosalicyclic acid, stained with Coomassie blue for 1 h and destained for 24 h. On day 5, the gel was scanned.
The peak and mean LDL particle diameter were obtained. The peak LDL particle diameter was defined as the size of the major LDL fraction. The mean LDL particle diameter was calculated to yield the mean diameter across the entire LDL particle profile. To achieve this, the peak area under the curve (volume) was calculated. For each portion, the particle size was calculated using the known reference sizes of LDL I, LDL II and LDL III. Then, the frequency for each particle was calculated (size Â volume). Finally, the sum of the frequencies was divided by the sum of the volumes to yield the mean particle diameter. Large LDL particles were defined as having a diameter 425.5 nm, and small LDL particles were defined as having a diameter p25.5 nm. LDL phenotype A (lager, more buoyant LDL) and phenotype B (sdLDL) were defined by the predominant types of LDL particles.
Commercially available assay kits were used for biochemical measurements. Enzymetric colorimetry (Roche Diagnostics GmbH; Mannheim, Germany) was used to measure the total concentrations of cholesterol, HDL cholesterol, TG and LDL cholesterol. HbA1c was measured by ion-exchange highperformance liquid chromatography (Variant II, Bio-Rad Laboratories, Hercules, CA, USA). Immunoturbidometry (Roche Diagnostics) was used for measurements of serum apolipoprotein A-1, B, CII and E levels. Fasting plasma insulin levels were measured using a double-antibody radioimmunoassay (Beckman Coulter Inc., Brea, CA, USA), and an enzymatic assay kit was used to measure the glucose concentrations. The homeostasis model assessmentinsulin resistance (IR) value was calculated by the following formula: (fasting plasma insulin (mIU ml À1 ) Â fasting plasma glucose (mmol l À1 ))/22.5.
Statistical analysis SPSS 17.0. (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The w 2 -test was used for categorical variables and one-way analysis of variance was used for continuous variables. Post hoc analysis was performed using the least significant difference. A P-value o0.05 was considered statistically significant. Correlation coefficients were determined according to the Pearson's correlation test. The results are presented as percentages for categorical variables and as mean ± s.d. for continuous variables. Multivariate analysis was performed using the logistic regression analysis.
Results
Baseline characteristics are shown in Table 1 . Age was greater in the non-MS/HTN group than in the non-MS/non-HTN group (60.21±12.78 versus 54.19 ± 14.47 years, Po0.001). Gender, body mass index, insulin, c-peptide, Hb A1c, C-reactive protein and the homeostasis model assessment index values were not significantly different between the non-MS/non-HTN and non-MS/HTN groups; however, waist circumference was significantly different. Medication history in regard to statin, omega-3 fatty acid, ezetimibe and fibrate use was not significantly different between the non-MS/non-HTN and non-MS/HTN groups. In regard to lipid profiles, plasma total cholesterol, LDL cholesterol, HDL cholesterol, TG, HLD-c/Apo A1, LDL-c/ApoB and apolipoprotein (A1, B, CII and E) levels were not significantly different between the non-MS/non-HTN and non-MS/HTN groups. However, significant differences in lipid profiles were found between the MS and non-MS groups (Table 2 ).
In the MS group, the proportion of sdLDL to total LDL was higher than in both the non-MS/non-HTN group (42.45±10.06 versus 37.74±8.46, Po0.001) and the non-MS/HTN group (42.45±10.06 versus 39.88±8.83, P ¼ 0.034; Figure 1 ). In the non-MS group, the proportion of sdLDL to total LDL was higher in the HTN group than in the non-HTN group (39.88±8.83 versus 37.74±8.46, P ¼ 0.046; Figure 1 ). The prevalence of pattern A and B LDL phenotypes was not significantly different between the non-MS/ non-HTN and the non-MS/HTN groups (92.7%/ 7.3% versus 88.9%/11.1%, P ¼ 0.554), although the prevalence of pattern A and pattern B was significantly different between the MS group and the non-MS group (72.7%/27.3% versus 88.9%/11.1% Figure 3 ), though the peak LDL particle diameter was not significantly different between the non-MS/HTN and non-MS/non-HTN groups (27.11±1.16 versus 27.32±1.01 nm, P ¼ 0.107).
In non-MS patients, the proportion of sdLDL to total LDL was not correlated with systolic blood pressure (correlation coefficient 0.106, P ¼ 0.064), DBP (correlation coefficient 0.086, P ¼ 0.132), and heart rate (correlation coefficient 0.064, P ¼ 0.266). In non-MS patients, the proportion of sdLDL to total LDL did not significantly associated with HTN, after adjustment for waist circumference, serum TG, age and statin use. (Table 3) Discussion In this study, the prevalence of patterns A and B LDL phenotypes was not different between the hypertensive and normotensive patient groups. The relative proportion of sdLDL in relation to total LDL was significantly higher in hypertensive patients without MS than in normotensive subjects in univariate analysis. But the difference of the proportion of sdLDL in relation to total LDL became insignificant by multivariate analysis. Therefore, we think that HTN per se does not increase the proportion of sdLDL but the conditions associated with HTN seem to attribute to increase the sdLDL proportion. As a predominance of sdLDL is a known cardiovascular risk factor, 20 p=0.039 Figure 3 Comparison of the peak particle diameter and the mean particle diameter of low-density lipoprotein between study groups. HTN, hypertension; MS, metabolic syndrome. Association of hypertension with small, dense low-density lipoprotein YK Kim et al (either in absolute or relative concentrations) and CVD risk. However, a recent review of 24 studies with LDL particle measurements in relation to CVD outcomes showed that Higher LDL particle number has been associated with CVD incidence, and that studies have not determined whether any measures of LDL subfractions add incremental benefit to traditional risk factor assessment based primarily on 10 studies with LDL analyzed by nuclear magnetic resonance. 23 They also concluded that gradient gel electrophoresis particle size measurements have provided more consistent evidence of additional benefit over standard lipid measurements. 23 We used the gradient gel electrophoresis method for LDL subfraction and found difference in LDL subfraction between hypertensive and normotensive subjects. One of the reasons for this conflicting result is because of comparability of methods for LDL subfraction determination. 24 Currently, the basic principle for LDL subfraction are on the basis of its particle size, untracentrifugal flotation, charge separation and differential precipitation techniques, and currently used procedures in published literature included nuclear magnetic resonance, ion mobility, LipoPrint (Quantimetrix, Redondo Beach, CA, USA), ultracentrifugation and gel electrophoresis and high performance gel filtration chromatography. However, there is no reference method for determining LDL subfractions or standardizing the different methods, and Chung et al. 25 reviewed that there was a wide range of agreement (from 7 to 94% concordance for classifying LDL patterns) among methods for LDL subfraction determinations. Unfortunately, different criteria and definitions were used among the articles to classify individuals with respect to CVD risk and no study used CVD or other clinical outcomes as an outcome measure. Assessments of the relationships of lipoprotein subfractions to CVD risk have most commonly been based on measurements of their absolute concentrations (for example, by nuclear magnetic resonance and ion mobility) or their relative distributions (for example, by gradient gel electrophoresis). For exact validation of LDL subfraction in clinical utilization, further studies are needed.
There are no reports indicating that the mechanism of sdLDL formation is attributable to blood pressure elevation, despite numerous studies of MS. One of the mechanisms leading to increased CVD in MS is associated with sdLDL, and several potentially contributing factors leading to sdLDL particle formation were studied. In MS, the mechanism for sdLDL formation is known to be related to IR and hypertriglyceridemia; this relationship was demonstrated in the Framingham Heart study. 18 Diabetes, MS, and IR all have associated atherogenic lipids, including a predominance of sdLDL, lower HDL cholesterol, and higher TG levels. [26] [27] [28] Goff et al. 29 reported that IR was associated with increased numbers of sdLDL particles in the Insulin Resistance Atherosclerosis Study. Central obesity is associated with increased CVD and elevated levels of sdLDL particles. Additionally, end-stage renal disease is also known to be related to the proportion of small LDL particles. 30 Most of these conditions are frequently associated with HTN, but the exact role of HTN in sdLDL formation is still obscure. Systolic blood pressure and DBP were significantly correlated with small LDL particle numbers in patients with MS. 18 Several studies reported the association of HTN with an elevation of sdLDL levels. Landray et al. 31 reported a preponderance of smaller LDL subfractions in patients with untreated HTN, but the study population did not completely exclude patients with MS or hypertriglyceridemia. Winkler et al. 32 also reported that 63% of nondiabetic hypertensive patients had sdLDL levels as elevated as diabetic patients; however, some of those patients had MS and/or hypertriglyceridemia. Additionally, Felmeden et al. 33 reported a greater proportion of the more atherogenic LDL subfractions, which are related to endothelial dysfunction, in 84 high-risk hypertensive patients recruited as part of the Anglo Scandinavian Cardiac Outcome Trial; these levels were reduced after 6 months of cardiovascular risk factor management. The subjects in this study were pure hypertensive patients without MS and/or hypertriglyceridemia; these were selected to exclude the effects of IR and hypertriglyceridemia on the formation of sdLDL. We demonstrated the typical step-ladder pattern of sdLDL proportion from control to HTN to MS patients. And we could not find any difference in concentration of apolipoprotein A and B or its ratio between the non-MS/non-HTN and the non-MS/HTN groups. IR and hypertriglyceridemia is also known to be associated with abdominal obesity measured by abdominal circumference and with age. In this study, statistical significance of sdLDL by HTN was disappeared after adjustment of these factors.
Statins are the most widely used cholesterollowering agents because of their beneficial vascular effects. We have investigated the effect of statin on sdLDL proportion and reported that statin decreases absolute amount of sdLDL but increases relative proportion of sdLDL due to the reduction of total LDL. 34 This result can explain that the vascular protective effects of statins are expected through an overall lowering of cholesterol despite of higher proportion of sdLDL by statin usage, even in hypertensive patients. This statin effect may be partially explained by the results of this study, though further investigations to clarify this are required. Another possible factor influencing sdLDL formation may be genetic differences in enzymes influencing lipid metabolism including lipoprotein lipase, apolipoprotein C-III, cholesterol ester transfer protein and/or hepatic lipase. The exact enzymes involved in elevated blood pressure are not known, but there are several reports supporting this hypothesis. Gene mutations in lipoprotein lipase are reported to increase susceptibility for preeclampsia and endophenotype of HTN. 35, 36 Polymorphism in the apolipoprotein C-III gene locus alters lipoprotein metabolism and can influence IR in essential hypertensive patients and increase the risk of CAD. 37, 38 We suggest that genetic traits or individual variation in these enzymes may be associated with HTN, without affecting hypertriglyceridemia or IR, through environmental factors, such as life style differences. These genetic traits or individual enzyme variations may result in subclinical lipid changes such as change in proportion of sdLDL that may affect occurrence of CAD with other CAD risk factors in hypertensive patients without MS. Therefore, we could not conjecture exact plausible mechanism of sdLDL formation related to blood pressure in this study. Although HTN per se does not increase the proportion of sdLDL, we think that HTN is a clinical syndrome that is frequently associated with conditions such as age, obesity and dyslipidemia, and increases sdLDL proportion, as a result of which HTN increases the risk of atherosclerotic vascular diseases. The difference in the proportion of sdLDL between individuals is not large, but the population of hypertensive patients is very large and its impact on precipitating CVD may therefore be significant. In this study, hypertensive patients without MS showed more tendency of increased rate of sdLDL particles than normotensive patients without MS.
This study has several limitations. First, this is a retrospective study and the number of enrolled patients was relatively small, which weakens the statistical power of our analysis. Second, the medication histories in regard to cholesterol-lowering agents were not surveyed perfectly. However, lipid profiles between the hypertensive and normotensive groups were not statistically different. Therefore, it can be inferred that the medication history in regard to cholesterol-lowering agents was not different between the two groups. Third, 59.0% of subjects in the non-MS HTN group were undergoing anti-hypertensive treatment. It is known that cardiovascular risk factor management, including control of HTN, improves LDL subfraction profiles. 33 Thus, change of the LDL subfraction profile by the usage of anti-hypertensive drugs can weaken the power of the our study results. Fourth, there are many methods for LDL subfraction determination. 25 We used amethod, gel electrophoresis, in determining LDL subfraction. We think this point will weaken the power of our study results.
In conclusion, in patients without MS, the proportion of atherogenic sdLDL particles are apt to higher in hypertensive patients but statistically insignificant. But sdLDL can have a part in occurrence of the CVD in hypertensive patients together other atherogenic factors. Further studies are needed to elucidate the relationship between HTN and sdLDL particles. Careful prescription of cholesterol-lowering agents could be considered in HTN patients regardless of the presence of MS.
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